Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021–May 2023

<b>Background:</b> European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of COVID-19 vaccines among HCWs against laboratory-confirmed SARS-CoV-2 infection. <b>Methods:</b> HCWs from 19 hospitals in 10 countries participated in a dynamic prospective cohort study, providing samples for SARS-CoV-2 testing at enrolment and during weekly/fortnightly follow-up. We measured the incidence during pre-Delta (2 May-6 September 2021), Delta (7 September-14 December 2021), and Omicron (15 December 2021-2 May 2023) waves. Using Cox regression, we measured the relative vaccine effectiveness (rVE) of the first COVID-19 booster dose versus primary course alone during Delta and Omicron waves. <b>Results:</b> We included a total of 3015 HCWs. Participants were mostly female (2306; 79%), with a clinical role (2047; 68%), and had a median age of 44 years. The overall incidence of SARS-CoV-2 infection was 3.01/10,000 person-days during pre-Delta, 4.21/10,000 during Delta, and 23.20/10,000 during Omicron waves. rVE was 59% (95% CI: -25; 86) during Delta and 22% (1; 39) during Omicron waves. rVE was 51% (30; 65) 7-90 days after the first booster dose during the Omicron wave. <b>Conclusions:</b> The incidence of SARS-CoV-2 infection among HCWs was higher during the Omicron circulation period. The first COVID-19 vaccine booster provided additional protection against SARS-CoV-2 infection compared to primary course vaccination when recently vaccinated <90 days. This multi-country HCW cohort study addressing infection as the main outcome is crucial for informing public health interventions for HCWs.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2024-11-19
DOI
https://doi.org/10.3390/vaccines12111295
Citations
5
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
1.95

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021–May 2023

Silvia Lamonica, Elza Barzdina, Albert Prats‐Uribe, Mihaela Lazăr et al.
5 citations
Vaccines
SARS-CoV-2 and COVID-19 Research
1.95
article

Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021–May 2023

Silvia Lamonica, Elza Barzdina, Albert Prats‐Uribe, Mihaela Lazăr, Georgios Panagiotakopoulos, Kyriaki Tryfinopoulou, Lauren Ferguson, Jonathan McGrath, Venerando Rapisarda, Victor Daniel Miron, Zvjezdana Lovrić Makarić, Goranka Petrović, Anneli Uusküla, Alma Kosa, Anna Spolti, Claire Kenny, Miriam Latorre-Millán, Antonella Agodi, Dace Zavadska, Kim Brolin, Corneliu Petru Popescu, Mihai Craiu, Rita Murri, Gordan Sarajlić, Camelia Savulescu, Dagne Grãvele, Sabrina Bacci, Martina Barchitta, Catherine Fleming, Ausenda Machado, Piotr Kramarz, Dainis Krieviņš, Vânia Gaio, Anthony Nardone, Carmen Muñoz‐Almagro, Ana Milagro, Colm J Bergin, Paolo Bonfanti, Viesturs Zvirbulis, Pilar Subirats, Ilze Āboliņa, Laura Clusa, Konstanty Szułdrzyński, Jacklyn Sui, Simin Aysel Florescu, Marina Amerali, Ana Palmira Amaral, Marianna Rossi, Miguel Cisneros, Katleen de Gaetano Donati, Liis Lohur
article en
5 citations

Abstract

<b>Background:</b> European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of COVID-19 vaccines among HCWs against laboratory-confirmed SARS-CoV-2 infection. <b>Methods:</b> HCWs from 19 hospitals in 10 countries participated in a dynamic prospective cohort study, providing samples for SARS-CoV-2 testing at enrolment and during weekly/fortnightly follow-up. We measured the incidence during pre-Delta (2 May-6 September 2021), Delta (7 September-14 December 2021), and Omicron (15 December 2021-2 May 2023) waves. Using Cox regression, we measured the relative vaccine effectiveness (rVE) of the first COVID-19 booster dose versus primary course alone during Delta and Omicron waves. <b>Results:</b> We included a total of 3015 HCWs. Participants were mostly female (2306; 79%), with a clinical role (2047; 68%), and had a median age of 44 years. The overall incidence of SARS-CoV-2 infection was 3.01/10,000 person-days during pre-Delta, 4.21/10,000 during Delta, and 23.20/10,000 during Omicron waves. rVE was 59% (95% CI: -25; 86) during Delta and 22% (1; 39) during Omicron waves. rVE was 51% (30; 65) 7-90 days after the first booster dose during the Omicron wave. <b>Conclusions:</b> The incidence of SARS-CoV-2 infection among HCWs was higher during the Omicron circulation period. The first COVID-19 vaccine booster provided additional protection against SARS-CoV-2 infection compared to primary course vaccination when recently vaccinated <90 days. This multi-country HCW cohort study addressing infection as the main outcome is crucial for informing public health interventions for HCWs.

VaccinesVol. 12(11)
Università Cattolica del Sacro Cuore (IT), Hospital Sant Joan de Déu Barcelona (ES), Carol Davila University of Medicine and Pharmacy (RO), Ollscoil na Gaillimhe – University of Galway (IE), Trinity College Dublin (IE), Vibhavadi Hospital (TH), Agostino Gemelli University Polyclinic (IT), University Hospital Galway (IE), Universitat Internacional de Catalunya (ES), University of Catania (IT), Centro Hospitalar Tondela-Viseu (PT), Hrvatski zavod za javno zdravstvo (HR), Pauls Stradiņš Clinical University Hospital (LV), Hospital Universitario Miguel Servet (ES), Children's Clinical University Hospital (LV), Institutul National pentru Sanatatea Mamei si Copilului "Alessandrescu-Rusescu" (RO), Policlinico Universitario di Catania (IT), Ministry of Interior and Administration (PL), Spitalul Clinic Dr. Victor Babes (RO), Instituto de Investigación Sanitaria Aragón (ES), National Institute of Health Dr. Ricardo Jorge (PT), National Public Health Organization (GR), Istituti di Ricovero e Cura a Carattere Scientifico (IT), St. James's Hospital (IE), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), Institut de Recerca Sant Joan de Déu, University of Tartu (EE), European Centre for Disease Prevention and Control (SE), University of Milano-Bicocca (IT)
European Centre for Disease Prevention and Control
Good health and well-being
Openalex Percentile: Top 13%
SARS-CoV-2 and COVID-19 Research
1.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.